Luxembourg recall on NOVOMIX 30 insulin pens
A type of insulin has been recalled from the Luxembourg market as a precaution, the department of health and European Medicines Agency have revealed.
The Novo Nordisk laboratory withdrew NOVOMIX 30 FlexPen 100 U/ml, an insulin injection pen used in the treatment of diabetes.
The recall was prompted by a quality defect occurring during the manufacture of cartridges, leading to a potential risk of underdosing or overdosing of insulin.
It concerns a limited number of pens, including lots CP50640, CP50914, CP50903, CP50928, CP50940 and CP51706.
Patients being treated with this product with a batch number that corresponds to one of those listed should return their pen to their pharmacist, who will issue an alternative.
Patients are warned against stopping their diabetes treatment.